microRNA Replacement Therapy
Press Releases

 
Press Releases
Date Title and Summary View
03-29-16 Management to host conference call and webcast today at 5 p.m. Eastern AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today reported financial results for...
03-22-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced that the Company will host a conference call and live webcast on Tuesday, March 29, 2016 at 5:00 p.m. ET...
02-03-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced its participation in two healthcare investor conferences during the month of February. C...
02-01-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the appointment of Peter Greenleaf to the Company's Board of Directors. Mr. Greenleaf brings over 20 yea...
12-02-15 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced that President and Chief Executive Officer Paul Lammers, M.D., M.Sc., will present a corporate overview ...
11-23-15 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapies, today announced that the Journal of the National Cancer Institute (JNCI) published new preclinical data demonstrating a nov...
11-13-15 Demonstrated confirmed partial responses in liver cancer and melanoma in Phase 1 clinical trial of lead product candidate MRX34 Completed IPO and concurrent private placement in October with aggregate gross proceeds of $65.5 million Strengthened management team with...
11-09-15 Data presented at AACR-NCI-EORTC International Conference AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the presentation of interim ...
10-27-15 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, announced the appointment of Dr. Miguel Barbosa, Ph.D. as Executive Vice President and Chief Scientific Officer. ...
10-06-15 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the closing of its initial public offering (IPO) of 6,250,000 shares of common stock at a public offering ...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
© 2017 Mirna Therapeutics, Inc. All Rights Reserved.